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In about 50 years, more than a quarter of the world will be
over 65 years of age. It’s even worse for some countries: the
projections are that at that time, Japan and Germany could
have 50% of their population in that category. The figure for
the US is estimated to be about one-third. The fastest
growing demographic segment in most developed nations is
people 85 and older. We are witnessing something utterly
unprecedented in human history: an explosion of people
well past their reproductive years. 
Evolution ceases to care about an organism when it has done
its job of passing its genes to the next generation. As far as
we know, natural selection does not increase the fitness of an
individual for later life; indeed, there is some reason to think
that longevity may be harmful in an evolutionary sense.
Older, non-reproducing organisms consume resources that
might better serve their younger, breeding brethren. And
chief among these resources is medical care, because old
age is a risk factor for just about everything bad that can
happen physically. 
Cancer (most types, anyway) and heart disease are just two
of the conditions that afflict the elderly much more fre-
quently than the young. Osteoporosis, pneumonia and other
potentially fatal infectious diseases are amongst the others;
and the list is a long one. But in almost no case is the deleteri-
ous effect of aging more dramatic than in the case of neuro-
logic diseases. With the exception of a few rarer ones such as
amyotropic lateral sclerosis (Lou Gehrig’s disease) and Hunt-
ington’s disease, which do their damage earlier, the inci-
dences of Alzheimer’s disease and other dementias and of
Parkinson’s disease and other movement disorders increase
exponentially starting at about age 60, such that by the time a
person reaches their mid-80s, their chance of showing symp-
toms of at least one of these conditions approaches 50%. The
prevalence of Alzheimer’s alone doubles every 5 years past
age 60. Right now, in the US, there are about 1 million people
with Parkinson’s disease and about 5 million with
Alzheimer’s disease (the corresponding figures for the UK
are just under a million Alzheimer’s cases and about
200,000 Parkinson’s cases). Exact figures are impossible to
get because there is overlap in symptoms between cognitive
and movement disorders in many patients and definitive
diagnosis is often not possible until autopsy. But what is
clear is that the major neurologic diseases cost the US about
a third of a trillion dollars a year, out of a gross domestic
product of $12.7 trillion. If you think that’s a lot, and it is,
then brace yourself: in fifty years, unless something is done,
all of these figures will at least triple. There will be 15 million
US Alzheimer’s patients, 3 million with Parkinson’s disease,
and the annual cost will be over 1 trillion dollars. Every other
western nation will experience similar increases. No
economy can survive that. 
One reason the future looks so bleak is that there is at
present not a single effective treatment for any of the major
neurologic disorders. Promising ones are claimed to be in
the pipeline for the big killers like stroke and Alzheimer’s,
but then, we’ve been hearing those promises for at least
three decades. And the ‘lesser’ scourges such as Parkinson’s
disease and other movement disorders are considered to
have prevalence too low for most major pharmaceutical
companies to be interested in developing therapeutics for
them. So bloated, and debt-laden, have some drug compa-
nies become after the recent round of mergers that a disease
offering only a million patients is considered unlikely to gen-
erate the return on investment needed. 
This would appear to leave a clear field for biotechnology
companies, but they haven’t exactly been leaping into the
breach either. Many appear to be scared off by the diffi-
culty in doing clinical trials for diseases like Parkinson’s (to
be fair, big drug companies are worried about the same
thing). Neurodegenerative diseases are typically slowly
progressing with variable rates of decline and complex
symptomology. Picking a suitable clinical end-point is hard
enough, but when you add to it the likely time required for
a trial for a disease like Parkinson’s, which typically has a20-year progression, it’s understandable that even the major
pharmaceutical companies are wary. 
Governments often need to step in when the private sector is
reluctant, and to some extent they have, but much of the
innovative research in neurodegenerative diseases is funded,
at least initially, by private foundations set up by patient
advocacy and support groups. Thanks to them, there has
been progress, but things are still moving very slowly. 
Ironically, neurologic diseases may be a lot easier to treat
than disorders like cancer. If you want to cure cancer, you
had better be perfect, because if you let even one rogue cell
escape, that may, in theory at least, be enough to start a fatal
metastasis. I don’t know about you, but I’m far from perfect -
just ask my research group. But if you want to ‘cure’
Alzheimer’s or Parkinson’s disease, which are typically late
onset and slowly progressing, you don’t have to be perfect.
Delay the average age of onset by a decade or two and the
problem becomes much less serious. Slow the rate of pro-
gression by just one order of magnitude and a fatal disease
may no longer be a significant problem for most people. In
other words, for neurodegenerative disorders, all that may
be required is to buy enough time. 
Increasing evidence suggests that genomics should be a sig-
nificant contributor to doing just that. Because the most
common forms of the major neurologic diseases are sporadic
and idiopathic, it was long thought that genetic factors
played a relatively minor role in susceptibility (compared
with, say, environmental factors and diet). But recent twin
studies in Scandinavia and elsewhere paint a very different
picture. Monozygotic twins show a high correlation in inci-
dence of Alzheimer’s disease compared with nonidentical
twins, where the correlation is low. The best current guess is
that more than 75% of the susceptibility to sporadic
Alzheimer’s disease may be due to genetic factors. The figure
for Parkinson’s disease is estimated to be lower, below 50%,
but still substantial. Since most neurologic disorders don’t
present with symptoms until a sizeable fraction of the rele-
vant neurons have already died off, many neurologists have
felt that preventative measures were a better long-term
strategy than trying to arrest the progress of the disease. The
problems are: how do you measure efficacy of prevention for
a sporadic disease, and how do you avoid having to give the
preventative drug to the entire elderly population? The
recent sad story of Vioxx, an arthritis painkiller that had to
be withdrawn from the market after it was linked to
increased incidences of heart attacks and strokes, shows
what can happen when a drug is administered to a larger
population than absolutely need it. 
But if the tools of genomics allow us to identify genetic risk
factors for the sporadic disease, then preventative measures
can focus on reducing the risks for that population only, down
to ‘normal’ levels, which in fact may be very small. The recent
discovery that Ashkenazi Jews who are carriers for Gaucher
disease are at increased risk of developing Parkinson’s disease
represents, I think, just the beginning of what should be a
massive effort to identify the haplotypes that predispose indi-
viduals to a high risk of neurodegenerative disease. 
Meanwhile, the incipient epidemic still needs to be checked.
The best hope short-term probably lies with drugs that slow
or arrest the neuronal decay. Finding them requires that the
clinical trials problem be solved, but I don’t think that may
be as daunting as it seems. All of the major neurologic dis-
eases have rarer, closely related conditions that are much
more rapid in their progression and that have death as a
clinical end-point. For example, although Parkinson’s
disease progresses very slowly, multiple system atrophy,
which has similar pathology and appears to involve many if
not most of the same molecular players, is usually fatal
within about five years of diagnosis. Using these faster dis-
eases as surrogates for the slower may be a way to design
clinical trials with a clear outcome (survival) and an accept-
able duration. But that requires accurate and early diagnosis
of these conditions, which currently is very difficult to do, as
they all resemble one another in many of their symptoms.
Microarray analysis of gene expression and other genomics
tools may help overcome this problem, which right now rep-
resents the major obstacle to progress. 
The hope then is that genomics will make it feasible for
biotechnology companies and large pharmaceutical firms to
expand the scope of their efforts in neurologic diseases. If
they don’t, we could be looking at a future in which the
human life span is continually extended but the quality of
that later life is horrible. I don’t know about the H5N1 virus
and the avian flu; as I’ve written previously in my column
(Genome Biology 2005, 6:121), the prospects for that epi-
demic are uncertain. But the coming neurologic crisis is an
epidemic that is as sure as anything I know of. And this one
won’t be confined to a third world country, or to some place
safely remote. The clock is ticking for all of us.
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